Skip to main content
SpringerLink
Log in

The Use of Tumor Markers in Bladder Cancer and Current Concepts on Clinical Applicability

  • Chapter
Bladder Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 147 Accesses

Abstract

In its broadest sense, a biomarker is anything that can be used to indicate the presence or nature of a disease. This definition includes techniques ranging from molecular analysis to image analysis and can utilize all of the research tools of modern medicine. Biomarkers can be used for either diagnosis or prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992; 19: 435.

    CAS  PubMed  Google Scholar 

  2. Murphy WM. Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990; 21: 886.

    Article  CAS  PubMed  Google Scholar 

  3. Shenoy UA, Colby TV, Schumann GB. Reliability of urinary cytodiagnosis in urothelial neoplasms. Cancer 1985; 56: 2041.

    Google Scholar 

  4. Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J, Hudson MA, Schellhammer PF, et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995; 154: 379.

    Article  CAS  PubMed  Google Scholar 

  5. Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997; 158: 801.

    Article  CAS  PubMed  Google Scholar 

  6. Bastacky S, Ibrahim S, Wilczynski SP, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer 1999; 87: 118.

    Article  CAS  PubMed  Google Scholar 

  7. Badalament RA, Hermansen DK, Kimmel M, Gay H, Herr HW, Fair WR, et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer 1987; 60: 1423.

    Article  CAS  PubMed  Google Scholar 

  8. Schwalb DM, Herr HW, Fair WR. The management of clinically unconfirmed positive urinary cytology. J Urol 1993; 150: 1751.

    CAS  PubMed  Google Scholar 

  9. Melamed MR. Flow cytometry for detection and evaluation of urinary bladder carcinoma. Semin Surg Oncol 1992; 8: 300.

    Article  CAS  PubMed  Google Scholar 

  10. de la Roza GL, Hopkovitz A, Caraway NP, Kidd L, Dinney CP, Johnston D, Katz RL. DNA image analysis of urinary cytology: prediction of recurrent transitional cell carcinoma. Mod Pathol 1996; 9: 571.

    PubMed  Google Scholar 

  11. Slaton JW, Dinney CPN, Veltri RW, Miller MC, Liebert M, O’Dowd GJ, Grossman HB. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol 1997; 158: 806.

    Article  CAS  PubMed  Google Scholar 

  12. Johnston B, Morales A, Emerson L, Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol 1997; 158: 2098.

    Google Scholar 

  13. Murphy WM, Rivera-Martinez I, Medina CA, Wright NJ, Wajsman Z. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol 1997; 158: 2102.

    Google Scholar 

  14. Sarosdy MF, Hudson MA, Ellis WJ, Soloway MS, deVere White RW, Sheinfeld J, et al. Detection of recurrent bladder cancer using a new one-step test for bladder tumor antigen. J Urol 1997; 157 (Suppl): 337.

    Google Scholar 

  15. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology 1997; 50: 882.

    Article  CAS  PubMed  Google Scholar 

  16. Pode D, Shapiro A, Wald M, Nativ O, Laufer M, Kaver I. Noninvasive detection of bladder cancer with the BTA stat test. J Urol 1999; 161: 443.

    Article  CAS  PubMed  Google Scholar 

  17. Abbate I, D’Introno A, Cardo G, Marano A, Addabbo L, Musci MD, et al. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer. Anticancer Res 1998; 18: 3803.

    CAS  PubMed  Google Scholar 

  18. Blumenstein BA, Ellis WJ, Ishak LM. The relationship between serial measurements of the level of a bladder tumor associated antigen and the potential for recurrence. J Urol 1999; 161: 57.

    Article  CAS  PubMed  Google Scholar 

  19. Carpinito GA, Stadler WM, Briggman JV, Chodak GW, Church PA, Lamm DL, et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996; 156: 1280.

    Article  CAS  PubMed  Google Scholar 

  20. Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997; 31: 163.

    CAS  PubMed  Google Scholar 

  21. Soloway MS, Briggman JV, Carpinito GA, Chodak GW, Church PA, Lamm DL, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996; 156: 363.

    Article  CAS  PubMed  Google Scholar 

  22. Stampfer DS, Carpinito GA, Rodriguez Villanueva J, Willsey LW, Dinney CP, Grossman HB, et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol 1998; 159: 394.

    Article  CAS  PubMed  Google Scholar 

  23. Serretta V, Lo Presti D, Vasile P, Gange E, Esposito E, Menozzi I. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients. Urology 1998; 52: 793.

    Article  CAS  PubMed  Google Scholar 

  24. Zippe C, Pandrangi L, Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol 1999; 161: 62.

    Article  CAS  PubMed  Google Scholar 

  25. Grossman HB, Washington RW Jr, Carey TE, Liebert M. Alterations in antigen expression in superficial bladder cancer. J Cell Biochem 1992; 161: 63.

    Article  Google Scholar 

  26. Bonner RB, Liebert M, Hurst RE, Grossman HB, Bane BL, Hemstreet GP 3rd. Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Cancer Epidemiol Biomarkers Prey 1996; 5: 971.

    CAS  Google Scholar 

  27. Fradet Y, Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt. Can J Urol 1997; 4: 400.

    PubMed  Google Scholar 

  28. Lokeshwar VB, Obek C, Soloway MS, Block NL. Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997; 57: 773.

    CAS  PubMed  Google Scholar 

  29. Pham HT, Block NL, Lokeshwar VB. Tumor-derived hyaluronidase: a diagnostic urine marker for high grade bladder cancer. Cancer Res 1997; 57: 778.

    CAS  PubMed  Google Scholar 

  30. Mao L, Schoenberg MP, Scicchitano M, Erozan YS, Merlo A, Schwab D, Sidransky D. Molecular detection of primary bladder cancer by microsatellite analysis. Science 1996; 271: 659.

    Article  CAS  PubMed  Google Scholar 

  31. Steiner G, Schoenberg MP, Linn JF, Mao L, Sidransky D. Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med 1997; 3: 621.

    Article  CAS  PubMed  Google Scholar 

  32. Belair CD, Yeager TR, Lopez PM, Reznikoff CA. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci USA 1997; 94: 13, 677.

    Google Scholar 

  33. Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N, et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 1997; 89: 724.

    Article  CAS  PubMed  Google Scholar 

  34. Muller M, Heine B, Heicappell R, Emrich T, Hummel M, Stein H, Miller K. Telomerase activity in bladder cancer, bladder washings and in urine. Int J Oncol 1996; 9: 1169.

    CAS  PubMed  Google Scholar 

  35. Kavaler E, Landman J, Chang YL, Droller MJ, Liu BCS. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer 1998; 82: 708.

    Article  CAS  PubMed  Google Scholar 

  36. Yokota K, Kanda K, Inoue Y, Kanayama H, Kagawa S. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. Br J Urol 1998; 82: 727.

    Article  CAS  PubMed  Google Scholar 

  37. Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku J, Nargund V, et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997; 79: 362.

    Article  CAS  PubMed  Google Scholar 

  38. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998; 52: 398.

    Article  CAS  PubMed  Google Scholar 

  39. Ramakumar S, Bhuiyan J, Besse JA, Roberts SC, Wollan PC, Blute ML, OKane DJ. Comparison of screening methods in detection of bladder cancer. J Urol 1999; 161: 388.

    Article  CAS  PubMed  Google Scholar 

  40. Ohyashiki K, Yahata N, Ohyashiki JH, Iwama H, Hayashi S, Ando K, et al. A combination of semiquantative telomerase assay and in-cell telomerase activity measurement using exfoliated urothelial cells for the detection of urothelial neoplasia. Cancer 1998; 83: 2554.

    Google Scholar 

  41. Muller M, Krause H, Heicappell R, Tischendorf J, Shay JW, Miller K. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 1998; 4: 1949.

    CAS  PubMed  Google Scholar 

  42. Esrig, D, Spruck CH 3rd, Nichols PW, Chaiwun B, Steven K, Groshen S, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993; 143: 1389.

    CAS  PubMed  Google Scholar 

  43. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, Zhang ZF, Rosai J, et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 1994; 56: 347.

    Article  CAS  PubMed  Google Scholar 

  44. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993; 53: 365.

    Article  CAS  PubMed  Google Scholar 

  45. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993; 85: 53.

    Article  CAS  PubMed  Google Scholar 

  46. Sarkis AS, Zhang ZF, Cordon-Cardo C, Melamed J, Dalbagni G, Sheinfeld J, et al. p53 nuclear overexpression and disease progression in Ta bladder carcinoma. Int J Oncol 1993; 3: 355.

    CAS  PubMed  Google Scholar 

  47. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, et al. Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994; 152: 388.

    CAS  PubMed  Google Scholar 

  48. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331: 1259.

    Article  CAS  PubMed  Google Scholar 

  49. Sarkis AS, Bajorin DF, Reuter VE, Herr HW, Netto G, Zhang ZF, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384.

    CAS  PubMed  Google Scholar 

  50. Kuczyk MA, Bokemeyer C, Serth J, Hervatin C, Oelke M, Hofner K, et al. p53 over-expression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995; 31A: 2243.

    Google Scholar 

  51. Serth J, Kuczyk MA, Bokemeyer C, Hervatin C, Nafe R, Tan HK, Jonas U. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995; 71: 201.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG, et al. Effect of p2l(WAF1/CIP1) expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998; 90: 1072.

    Article  CAS  PubMed  Google Scholar 

  53. Logothetis CJ, Xu HJ, Ro JY, Hu SX, Sahin A, Ordonez N, Benedict WF. Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 1992; 84: 1256.

    Article  CAS  PubMed  Google Scholar 

  54. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z, Reuter VE. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992; 84: 1251.

    Article  CAS  PubMed  Google Scholar 

  55. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090.

    CAS  PubMed  Google Scholar 

  56. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL, Benedict WF. p53 and RB expression predict progression in Tl bladder cancer. Clin Cancer Res 1998; 4: 829.

    CAS  PubMed  Google Scholar 

  57. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retino-blastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18: 1197.

    Article  CAS  PubMed  Google Scholar 

  58. Cordon-Cardo C, Zhang Z. F, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997; 57: 1217.

    CAS  PubMed  Google Scholar 

  59. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga ML, Seymour GJ, Lavin MF. Immunohistological expression of p53 in primary pTl transitional cell bladder cancer in relation to tumour progression. Br J Urol 1994; 73: 526.

    Article  CAS  PubMed  Google Scholar 

  60. Vet JA, Bringuier PP, Poddighe PJ, Karthaus HF, Debruyne FM, Schalken JA. p53 mutations have no additional prognostic value over stage in bladder cancer. Br J Cancer 1994; 70: 496.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. Jahnson S, Risberg B, Karlsson MG, Westman G, Bergstrom R, Pedersen J. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy. Eur Urol 1995; 28: 135.

    CAS  Google Scholar 

  62. Jahnson S, Karlsson MG. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy. J Urol 1998; 160: 1291.

    Article  CAS  PubMed  Google Scholar 

  63. Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer. J Urol 1996; 155: 1784.

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. H. Barton Grossman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Urology, Mount Sinai School of Medicine, New York, NY, USA

    Michael J. Droller MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Grossman, H.B. (2001). The Use of Tumor Markers in Bladder Cancer and Current Concepts on Clinical Applicability. In: Droller, M.J. (eds) Bladder Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-097-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-097-1_6

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-202-5

  • Online ISBN: 978-1-59259-097-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation